Novartis is paying Chengdu Baiyu Pharmaceutical $70 million to add to its crop of cancer candidates. | Novartis is paying ...

BAIYU Holdings shares touched a 52-week low as the stock returned to Nasdaq, over a month after the Securities and Exchange Commission temporarily suspended trading. However, shares could possibly ...

中国深圳 - 作为一家知名的B2B电子商务和供应链服务提供商，BAIYU Holdings, Inc. (NASDAQ: BYU) 已就纳斯达克摘牌公司证券的决定提出上诉。该上诉已提交给纳斯达克听证小组，对纳斯达克工作人员基于公司近期业务发展的披露和尽职调查问题而做出的决定提出异议。 10月4日，BAIYU收到了纳斯达克的通知，随后公司聘请了Dickinson Wright, PLLC的Jacob ...

BAIYU Holdings, Inc. (Nasdaq: BYU) (the "Company" or "BAIYU"), a leading B2B bulk commodity e-commerce platform and supply chain service provider, today announced that it has filed timely a formal ...

Chengdu Baiyu Pharmaceutical yesterday announced that it has entered into an exclusive license agreement with Swiss pharma ...

BAIYU Holdings, Inc. (Nasdaq: BYU) (the "Company" or "BAIYU"), a leading B2B bulk commodity e-commerce platform and supply ...

CHENGDU, China I October16, 2024 I Chengdu Baiyu Pharmaceutical Co., Ltd. ("Baiyu") today announced that it has entered into an exclusive license ...

SHENZHEN, China, Oct. 8, 2024 /PRNewswire/ -- BAIYU Holdings, Inc. (Nasdaq: BYU) (the "Company" or "BAIYU"), a leading B2B bulk commodity e-commerce platform and supply chain service provider ...

Novartis is spending $70 million upfront on a small molecule antitumor drug from the Chinese biotech Chengdu Baiyu. The Swiss ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...